Answers are grounded in this paper and cite their sources.
Observational analysis shows ribociclib induces cardiotoxicity in human engineered heart tissues, suggesting mechanism via E2F1 and spliceosome impairment.
Background Ribociclib, a novel chemotherapeutic agent for metastatic breast cancer, functions as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Its mechanism of action involves the CDK4/6-Rb-E2F1 pathway. Ribociclib use has very recently been associated with development of heart failure (HF), yet the causality of its cardiac effects remains to be explored. Aims This study aims to investigate ribociclib's cardiotoxic effects in dynamic human engineered heart tissues (dyn-EHTs), focusing on the CDK4/6-Rb-E2F1 axis. Methods Dyn-EHTs were generated using human induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) and treated with repeated doses of ribociclib (7 µM) to mimic clinical drug administration. To determine the regulatory role of downstream E2F1 in this dysfunction, an E2F1-overexpressing iPSC line was made with which contractility assays were performed and dyn-EHTs were generated. To explore underlying mechanisms of E2F1 involvement, RNA-sequencing was performed on E2F1-overexpressing dyn-EHT (n=4) and scrambled (SCR) dyn-EHT (n=4). Results Upon treatment with ribociclib, dyn-EHTs exhibited a 17.0% ±4.3% (p<0.001) increase in tissue dilatation, an 8.9%±4% (p<0.001) decrease in systolic force generation, and a 22.1%±5.7% (p<0.001) increase in systolic stress, indicating significant cardiac dysfunction. Overexpression of E2F1 in iPSCs resulted in a threefold increase in E2F1 protein expression and successfully mitigated the ribociclib-induced tissue dilatation (p=0.007), decreased systolic force generation (p=0.005), and increased systolic stress (p=0.004 ) of SCR tissues. RNA sequencing revealed impairment of spliceosome assembly as an underlying pathway in the control dyn-EHT that is attenuated in the E2F1 overexpressed tissues. Conclusions Our study demonstrates that ribociclib induces significant cardiotoxic effects in dyn-EHTs and iPSC-CMs through the CDK4/6-Rb-E2F1 pathway and could be caused by impaired spliceosome assembly. The prevention of these effects by E2F1 overexpression highlights this pathway's involvement in ribociclib's cardiotoxic profile. These findings emphasize the need for careful cardiac monitoring in patients treated with CDK4/6 inhibitors and suggest further research into specific mechanisms of cardiotoxicity in cancer therapeutics.
No takes yet. Share an insight, caveat, or question.
Pet et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: